ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjogren’s syndrome"

  • Abstract Number: 1431 • ACR Convergence 2024

    Computational Systems Biology Approach to Unveil Molecular Interactions in Sjogren’s Disease Pathogenesis

    Sacha E Silva Saffar1, Jacques-Eric Gottenberg2, Michele Bombardieri3, Divi Cornec4, Jacques-Olivier Pers4, Marta Alarcon-Riquelme5, Philippe Moigeon6, Michael Barnes7, Sandra Ng8, Wan Fai Ng9, Xavier Mariette10, Gaetane Nocturne10 and Anna Niaraki11, 1University Paris Saclay, Le Kremlin Bicetre, France, 2Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 3Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 4University of Brest, Brest, France, 5Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 6Servier Laboratories, France, Gif sur Yvette, France, 7William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, 8Centre for Translational Bioinformatics, William Harvey Research Institute, London, United Kingdom, 9Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, 10Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 11University of Toulouse, Toulouse, France

    Background/Purpose: Sjögren's disease (SjD) presents an unmet medical challenge as there is currently no cure. Despite advances in understanding the immunopathogenesis of SjD, there is…
  • Abstract Number: PP13 • ACR Convergence 2023

    My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me

    Lisa Rubenstein, Sjögren's Foundation, Los Angeles, CA

    Background/Purpose: Being diagnosed with Sjögren’s has been a life changing event for me.I was diagnosed in 2013 after suffering from various odd ailments. Ultimately, extreme…
  • Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium

    The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort

    Stacy Ardoin1, Stephen Balevic 2, Aimee Hersh 3, Yukiko Kimura 4, Andrea Knight 5, Laura Schanberg 6, Mary Beth Son 7 and Timothy Beukelman 8 for the CARRA investigators, 1Nationwide Children's Hospital, Columbus, 2Duke University, Hillsborough, 3University of Utah Primary Children's Hospital, Salt Lake City, 4Hackensack Meridian School of Medicine, Hackensack, 5SickKids Research Institute, Toronto, Canada, 6Duke Children's Hospital & Health Center, Durham, North Carolina, 7Boston Children's Hospital, Boston, Massachusetts, 8University of Alabama at Birmingham, Birmingham

    Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…
  • Abstract Number: 056 • 2020 Pediatric Rheumatology Symposium

    Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series

    Shawn Mahmud1, Danielle Bullock 1, Colleen Correll 1, Patricia Hobday 2, Mona Riskalla 3, Richard Vehe 4 and Bryce Binstadt 1, 1University of Minnesota, Minneapolis, 2Minneapolis, 3University of Minnesota, Minneapolis, Minnesota, 4University of Minnesota, Roseville

    Background/Purpose: Non-criteria antiphospholipid antibodies (NC-aPL) bind molecules such as phosphatidylethanolamine (PE), phosphatidylserine (PS), and prothrombin (Pt), but not the targets of routine antiphospholipid (aPL) testing…
  • Abstract Number: 1451 • 2019 ACR/ARP Annual Meeting

    Histological Characteristics in SICCA Syndrome – Clinical and Serological Association

    Maria de Lourdes Flores 1, Gabriela Alejandra Gutierrez-Robles 1, Flavio Cesar Estrada-Gil 1, Miguel Alejandro Davalos-Benitez 1, Jorge Ernesto Garcia-Alvarado 1, Alejandra de Lourdes Farias-Sierra1, Ignacio Garcia-De La Torre 2, Gerardo Orozco-Barocio 1, Carlos Gerardo Riebeling-Navarro 3 and Arnulfo Hernan Nava-Zavala 4, 1HGO SSJ, U de G, PNPC CONACYT, Guadalajara, Mexico, 2Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Jalisco, Mexico, 3UIEC UMAE HP CMN-SXXI IMSS / UNAM, Ciudad de Mexico, Mexico, 4UIB02 UMAE HE CMNO IMSS / HGO SSJ / PIM UAG / PNPC U de G, Guadalajara, Mexico

    Background/Purpose: The xerostomia and/or xerophtalmia (SICCA syndrome: items I and II of 2002 AECG criteria) are conspicuous characteristics of primary Sjögren´s syndrome (pSS). pSS diagnostic…
  • Abstract Number: 1906 • 2019 ACR/ARP Annual Meeting

    Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)

    Torsten Diekhoff 1, Maximilian Posch 2, Frank Wagner 2, Thomas Fischer 1, Quirino Schefer 2, Thomas Dörner 3, Didier Laurent 4, Yue Li 4 and Stephen Oliver4, 1Charité University Hospital, Berlin, Germany, 2Charité Research Organisation, Berlin, Germany, 3Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 4Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: To use ultrasound (US) to demonstrate that ianalumab, a monoclonal antibody with dual mechanisms-of-action of BAFF:BAFF-R blockade and enhanced, ADCC-mediated B cell depletion, can…
  • Abstract Number: 2431 • 2019 ACR/ARP Annual Meeting

    Extracellular Vesicles in Primary Sjögren’s Syndrome: A Promising Source for Novel Proteomic Biomarkers

    Chiara Baldini1, Francesco Finamore 2, Francesco Ferro 1, Silvia Rocchiccioli 2, Marta Mosca 3, Letizia Mattii 4 and Antonella Cecchettini 4, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, 2National Research Council – Clinical Institute of Physiology, PISA, Italy, 3Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, 4University of Pisa, Pisa, Italy

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex autoimmune disorder characterized by the specific involvement of salivary and lachrymal glands. In the recent past several…
  • Abstract Number: 1452 • 2019 ACR/ARP Annual Meeting

    Comparison of Clinical Phenotype, Serological Characteristics and Histologic Features Between Males and Females Patients with Primary Sjögren’s Syndrome (pSS)

    Loukas Chatzis1, Saviana Gandolfo 2, Francesco Ferro 3, Marco Binutti 2, Valentina Donati 4, Sara Zandonella Callegher 5, Vasilis Pezoulas 6, Aliki Venetsanopoulou 7, Argyropoulou Ourania 7, Georgios Michalopoulos 7, maria pappa 7, Clio Mavragani 7, Dimitris fotiadis 8, Chiara Baldini 3, Salvatore De Vita 2, Athanasios Tzioufas 1 and Andreas Goules 7, 1Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 2Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, 3Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, 4University of Pisa, Pisa, 5Rheumatology Clinic, Udine University Hospital, Udine, Italy, Udine, Italy, 6Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, GR45110, Ioannina, Greece, Ioannina, Greece, 7Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 8Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Ioannina, Greece

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a female predominant autoimmune disease and very few studies have been conducted to investigate the phenotypic differences of the…
  • Abstract Number: 2413 • 2019 ACR/ARP Annual Meeting

    LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome

    Bruno Cenni1, Peter End 1, Maciej Cabanski 1, Annamaria Jakab 1, Enrico Funhoff 1, Magdalena Kistowska 1, Arvind Kinhikar 2, Alessio Maiolica 1, Masaru Hirano 3, Barbara Nuesslein-Hildesheim 1, Amanda Littlewood-Evans 1, Daniela Angst 1, Robert Pulz 4 and Martin Kaul 1, 1Novartis Institutes for BioMedical Research, Basel, Switzerland, 2Novartis Institutes for BioMedical Research, Cambridge, MA, 3Novartis Institutes for BioMedical Research, Tokyo, Japan, 4Novartis Institues for BioMedical Research, Basel, Switzerland

    Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a cytoplasmic tyrosine kinase selectively expressed in B cells, macrophages, mast cells and basophils. The essential role of BTK…
  • Abstract Number: 2432 • 2019 ACR/ARP Annual Meeting

    Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts

    Saviana Gandolfo1, Cinzia Fabro 1, Serena Colafrancesco 2, Francesco Carubbi 3, Francesco Ferro 4, Elena Bartoloni 5, Efstathia Kapsogeorgou 6, Andreas Goules 6, Luca Quartuccio 1, Roberta Priori 2, Alessia Alunno 5, Guido Valesini 2, Roberto Giacomelli 3, Roberto Gerli 5, Chiara Baldini 4, Athanasios Tzioufas 6 and Salvatore De Vita 1, 1Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, 2Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, Roma, Italy, 3Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Italy, L'Aquila, Italy, 4Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, 5Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, 6Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece

    Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been implicated in primary Sjögren’s syndrome (pSS) and related B-cell lymphoproliferation / lymphoma (NHL) by tissue studies on salivary…
  • Abstract Number: 1453 • 2019 ACR/ARP Annual Meeting

    Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome

    Eun Hye Park1, You-Jung Ha 1, Eun Ha Kang 1, Yeong-Wook Song 2 and Yun Jong Lee 3, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, 2Seoul National University Hospital, Seoul, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea

    Background/Purpose: The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) and EULAR SS Patient-Reported Index (ESSPRI) have been validated as disease activity and outcome measures…
  • Abstract Number: 2414 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial

    Jolien van Nimwegen1, Esther Mossel 1, Robin Wijnsma 1, Greetje van Zuiden 1, Konstantina Delli 1, Alja Stel 1, Bert van der vegt 1, Erlin Haacke 1, Lisette Olie 1, Leonie Los 1, Gwenny Verstappen 1, Sarah Pringle 1, Fred Spijkervet 1, Frans Kroese 1, Arjan Vissink 1, Suzanne Arends 2 and Hendrika Bootsma 3, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, 3University of Groningen, Groningen, Netherlands

    Background/Purpose: Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. The Abatacept Sjögren Active Patients phase…
  • Abstract Number: 2433 • 2019 ACR/ARP Annual Meeting

    Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)

    Saviana Gandolfo1, Marco Binutti 1, Elena Doriguzzi Breatta 1, Cinzia Fabro 1 and Salvatore De Vita 1, 1Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy

    Background/Purpose: Fatigue is one of the most prevalent and impacting symptoms in primary Sjögren’s syndrome (pSS), significantly impairing the patient quality of life. To date,…
  • Abstract Number: 1454 • 2019 ACR/ARP Annual Meeting

    Sjӧgren’s Syndrome Foundation National Survey: The Impact and Burden of Oral Symptoms

    Sara McCoy1, Christie Bartels 2, Esen Akpek 3, Ian Saldanha 4, Vatinee Bunya 5, Matthew Makara 6 and Alan Baer 7, 1University of Wisconsin School of Medicine and Public Health, Madison, 2University of Wisconsin School of Medicine and Public Health, Madison, WI, 3Johns Hopkins University, Baltimore, 4Brown University School of Public Health, Providence, RI, 5University of Pennsylvania, Philadelphia, PA, 6Sjogren's Syndrome Foundation, Reston, VA, 7Johns Hopkins University, Baltimore, MD

    Background/Purpose: Sjӧgren’s syndrome (SS) is the second most common systemic autoimmune disease, typically characterized by ocular and oral sicca.  SS is associated with reduced quality…
  • Abstract Number: 2415 • 2019 ACR/ARP Annual Meeting

    Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients

    Yash Gandhi1, Mehmooda Shaikh 2, Blisse Vakkalagadda 1, Grigor Abelian 1, Neelanjana Ray 1, Robert Wong 1 and Bindu Murthy 1, 1Bristol-Myers Squibb, Princeton, 2Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Abatacept (ABA) has proven efficacy in autoimmune diseases and is being evaluated in pSS. The purpose of this investigation was to evaluate the pharmacokinetics…
  • 1
  • 2
  • 3
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology